FDA may have reached a new milestone in its effort to incorporate patient views into the drug review process when a Duchenne muscular dystrophy patient group obtained a prominent position in the eteplirsen advisory committee meeting presentations.
Duchenne Group's Presentation Is Milestone For Patient Involvement
Advocacy group gets portion of Sarepta's formal presentation period to present eteplirsen patient experience data, believed to be a first for an advisory committee meeting. Will it become commonplace?